Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Older age, CRP portend deaths in COVID-19 patients with diabetes
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
Older age, CRP portend deaths in COVID-19 patients with diabetes
13 Oct 2021Sustained caloric restriction reduces more fat than muscle, organ tissue
Calorie restriction (CR) for 2 years in young individuals without obesity significantly impacts body composition, including a preferential loss of adipose tissue, such as visceral fat, over muscle and organ tissue, a recent study has shown.
Sustained caloric restriction reduces more fat than muscle, organ tissue
12 Oct 2021Obesity may predispose individuals to early-onset colorectal adenocarcinoma
Individuals with obesity are at higher risk of developing early-onset colorectal adenocarcinoma compared with their normal-weight counterparts, as reported in a study.
Obesity may predispose individuals to early-onset colorectal adenocarcinoma
12 Oct 2021CV risk remains elevated in metabolically healthy obese
Individuals who are obese but without metabolic abnormalities (metabolically healthy obese [MHO]) have an elevated risk of developing MACE-HF*, new-onset heart failure (HF), and new-onset atrial fibrillation (AF), according to a French study presented at EASD 2021.
CV risk remains elevated in metabolically healthy obese
08 Oct 2021Ketone supplements may promote better brain health in obese adults
Ketone supplements containing β-hydroxybutyrate yield potential neurocognitive benefits in individuals with obesity, specifically bolstering cognitive function and increasing cerebral blood flow, as reported in a recent study.
Ketone supplements may promote better brain health in obese adults
08 Oct 2021Is liraglutide cardioprotective in T2D patients?
In individuals with type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide appeared to yield a cardioprotective benefit, data from the secondary endpoint analysis of the LIRAFLAME* trial suggests.